+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023- Product Image
Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023- Product Image

Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4825989
  • Report
  • August 2019
  • Region: Global
  • 133 pages
  • TechNavio

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi.
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Gallbladder Cancer Therapeutics Market: About this market

The gallbladder cancer therapeutics market considers sales from both combination therapy and monotherapy. Our analysis also considers the sales of gallbladder cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high therapeutic efficacy of these drugs will play a significant role in the combination therapy segment to maintain its market position. Also, our global gallbladder cancer therapeutics market report looks at factors such as strong incidence of gallbladder cancer in developing countries, rising risk factors for gall bladder cancer, and use of chemotherapy as a therapeutic approach. However, uncertainties in the side effect associated with chemotherapy, lack of diagnostic antigens for gallbladder cancer, and low incidence rate of disease in developed countries may hamper the growth of the global gallbladder cancer therapeutics industry over the forecast period.

Global Gallbladder Cancer Therapeutics Market: Overview

Rising risk factors for gallbladder cancer

Rise in the occurrence of cholelithiasis, chronic inflammation, and gall bladder polyps will increase the risk of developing gall bladder cancer, inducing the demand gallbladder cancer therapeutics. The rising availability of financial assistance programs is further helping patients in availing these high-cost treatments. This will lead to the expansion of the global gallbladder cancer therapeutics market at a CAGR of almost 5% during the forecast period.

The advent of targeted therapy

The global gallbladder cancer therapeutics market is witnessing the advent of immunotherapy as a potential therapeutic for the treatment of biliary tract cancer, including gallbladder cancer. The ongoing research in this is expected to facilitate the approval process of this drug. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global gallbladder cancer therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gallbladder cancer therapeutics manufacturers, that include Bristol-Myers Squibb Co., Eli Lilly, and Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi.

Also, the gallbladder cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Strong pipeline
  • Advent of targeted therapy
  • Strategic alliances
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Some late-stage molecules for biliary tract cancer and global gallbladder cancer
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Incidence rate of gallbladder cancer in various developing countries - 2015
Exhibit 44: Frequency of side effects associated with chemotherapy
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 52: Bristol-Myers Squibb Co. - Business segments
Exhibit 53: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 54: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 55: Bristol-Myers Squibb Co. - Key offerings
Exhibit 56: Bristol-Myers Squibb Co. - Key customers
Exhibit 57: Eli Lilly and Co. - Vendor overview
Exhibit 58: Eli Lilly and Co. - Business segments
Exhibit 59: Eli Lilly and Co. - Organizational developments
Exhibit 60: Eli Lilly and Co. - Geographic focus
Exhibit 61: Eli Lilly and Co. - Segment focus
Exhibit 62: Eli Lilly and Co. - Key offerings
Exhibit 63: Eli Lilly and Co. - Key customers
Exhibit 64: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 70: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 71: Pfizer Inc. - Vendor overview
Exhibit 72: Pfizer Inc. - Business segments
Exhibit 73: Pfizer Inc. - Organizational developments
Exhibit 74: Pfizer Inc. - Geographic focus
Exhibit 75: Pfizer Inc. - Segment focus
Exhibit 76: Pfizer Inc. - Key offerings
Exhibit 77: Pfizer Inc. - Key customers
Exhibit 78: Sanofi - Vendor overview
Exhibit 79: Sanofi - Business segments
Exhibit 80: Sanofi - Organizational developments
Exhibit 81: Sanofi - Geographic focus
Exhibit 82: Sanofi - Segment focus
Exhibit 83: Sanofi - Key offerings
Exhibit 84: Sanofi - Key customers
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: Definition of market positioning of vendors
    Note: Product cover images may vary from those shown

    FEATURED COMPANIES

    • Bristol-Myers Squibb Co.
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Sanofi.
    • MORE
    The following companies are recognised as the key players in the global gallbladder cancer therapeutics market: Bristol-Myers Squibb Co., Eli Lilly, and Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi.

    Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of targeted therapy.”

    According to the report, one of the major drivers for this market rising risk factors for gallbladder cancer.

    Further, the report states that one of the major factors hindering the growth of this market is the side effects associated with chemotherapy.

    The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
    Note: Product cover images may vary from those shown
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Sanofi.
    Note: Product cover images may vary from those shown

    Loading
    LOADING...

    Adroll
    adroll